Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations

Phase 1

Completed

• Conditions: Choroideremia; CHM (Choroideremia) Gene Mutations
• Interventions: Biological: AAV2-hCHM

• Registration Number: NCT02341807
• Lead Sponsor: Spark Therapeutics, Inc.

Brief Summary

This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.

Detailed Description

The primary objective is to evaluate the safety and tolerability of subretinal administration of AAV2-hCHM, in an inter-subject group dose escalation in individuals with choroideremia, based on a comprehensive clinical monitoring plan. The secondary objectives are to define the dose of AAV2-hCHM required to achieve stable, or improved, visual function/functional vision and to assess development of immune responses to adeno-associated virus vector, serotype 2 (AAV2) and Rab escort protein 1 (REP-1).

Study Timeline

• Study First Submitted: 2015-01-12
• Study First Submitted QC: 2015-01-14
• Study Start: 2015-01-15
• Study First Posted: 2015-01-19
• Primary Completion: 2022-10-12
• Study Completion: 2022-10-12
• Results First Submitted: 2023-10-12
• Results First Submitted QC: 2023-10-12
• Results First Posted: 2023-11-02
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-23
• Last Update Posted: 2024-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 15

Inclusion Criteria

• Male at least 18 years of age diagnosed with CHM gene mutation
• Central visual field (VF) <30° in any of the 24 meridians (using Goldmann perimetry III4e isopter) in the eye to be injected
• Any evidence of functioning outer retinal cells within the central 10°

Exclusion Criteria

• Previous history of ocular inflammatory disease (uveitis)
• Prior intraocular surgery within six months
• Participation in a previous gene therapy research trial within one year of enrollment or participation in any other ocular gene therapy trial
• Participation in a clinical study with an investigational drug in the past six months
• Grossly asymmetrical disease, or other eye morbidity, which may render the contralateral eye ineffective as a control
• Visual acuity <20/200 on standard Early Treatment of Diabetic Retinopathy Study (ETDRS) testing in the eye to be injected
• Presence of disease which may preclude the participant from participation in this trial
• Use of medications known to be neuroprotective or retino-toxic that could potentially interfere with the disease process and/or cause ocular adverse events; individuals who discontinue use of these compounds for 6 months may become eligible
• Identification by the investigator as being unable or unwilling to perform/be compliant with study procedures.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1: AAV2-hCHM Dose 1	AAV2-hCHM	Single, unilateral subretinal administration of a single low dose range of AAV2-hCHM.
Cohort 3 (Expansion Cohort): AAV2-hCHM Dose 2	AAV2-hCHM	Single, unilateral subretinal administration of a single high dose range of AAV2-hCHM.
Cohort 2: AAV2-hCHM Dose 2	AAV2-hCHM	Single, unilateral subretinal administration of a single high dose range of AAV2-hCHM.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	Up to 5 years	An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were AEs that occurred on or after the day of study drug administration. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Anti-AAV2 Viral Capsid Antibody Titers That Rose Above Baseline At Least Once After Dosing	Up to 2 years	Number of participants who were found to have quantifiable levels (above 1.55 micrograms \[μg\]/milliliter \[mL\]) of Anti-AAV2 viral capsid antibodies titer in the blood at least 1 study visit up to 2 years were reported.
Number of Participants With Cellular Immune Response to Rab Escore Protein-1 (REP-1) Through Interferon Gamma ELISPOT Assay	Up to 2 years	Interferon gamma ELISpot assays were used to evaluate the cellular immune response to REP-1 antigen in collected PBMC samples. Number of participants who demonstrated immune response to the REP-1 antigen were reported.
Number of Participants With Cellular Immune Response to AAV2 Through Interferon Gamma Enzyme-linked Immunosorbent Spot (ELISpot) Assay	Up to 2 years	Interferon gamma ELISpot assays were used to evaluate the cellular immune response to AAV2 antigen in collected peripheral blood mononuclear cell (PBMC) samples. Number of participants who demonstrated immune response to the AAV2 antigen were reported.

Trial Locations

Locations (3)

Children's Hospital of Philadelphia; 🇺🇸 Philadelphia, Pennsylvania, United States

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Massachusetts Eye and Ear Infirmary; 🇺🇸 Boston, Massachusetts, United States